安进Amgen Inc. (AMGN) 2022年年度报告「NASDAQ」.pdf

1、2023 Amgen Inc.All Rights Reserved.2022 Letter to Shareholders|Amgen2TO MY FELLOW SHAREHOLDERS:Amgen performed very effectively in 2022,reaching roughly 10 million patients around the world with our approved medicines,advancing many promising new medicines,delivering strong financial performance,and

2、 keeping the Company on track to achieve attractive growth through the end of the decade.Total revenues in 2022 were up 1%from the prior year to a record$26.3 billion.We also achieved record non-GAAP earnings per share of$17.69,up 27%from the prior year,and free cash flow of$8.8 billion.1 In a chall

3、enging year for the stock market as a whole,Amgen delivered total shareholder return in 2022 of 20%,ahead of the S&P 500 and the NASDAQ Biotechnology indices,both of which 1.Non-GAAPfinancialmeasures.SeereconciliationstoU.S.generallyacceptedaccountingprinciples(GAAP)accompanyingthisletter.declined l

4、ast year.We returned approximately$10.5 billion to shareholders in 2022 through share repurchases and dividends,with our dividend increasing for the eleventh consecutive year,up 10%per share over 2021.Our portfolio now includes 27 approved medicines,16 of which generated record 2022 sales and nine o

5、f which generated 2022 sales in excess of$1 billion.Looking across our portfolio as a whole,we achieved healthy volume growth of 9%in 2022,partially offset by a 5%decline in net selling price.A number of our innovative medicines performed particularly well last year,including our cholesterol treatme

6、nt Repatha(sales+16%versus the prior year),our osteoporosis medicines EVENITY(+48%)and Prolia(+12%),and several of our oncology and hematology therapies,such as Nplate(+27%),BLINCYTO(+24%),and KYPROLIS(+13%).Two of our newest innovations LUMAKRAS/LUMYKRAS to treat a type of non-small cell lung cance